Reconstructed-data analysis: newer BCG-unresponsive NMIBC drugs do not outperform gem/doce
Retrospective · Urol Oncol · 2026-11-11. Number 2 in the UrologyWatch Top 5 for November 11, 2026.
Using reconstructed individual patient data from registration trials, researchers found that none of the FDA-approved BCG-unresponsive NMIBC therapies (nadofaragene, pembrolizumab, nogapendekin alfa inbakicept, TAR-200) showed higher 3-month complete response, durability of response, or disease-free survival than intravesical gemcitabine/docetaxel; gem/doce had higher papillary-cohort DFS than pembrolizumab…
Why it matters: Raises the question of whether gem/doce should remain the benchmark for newer approved agents, though cross-trial, reconstructed-data comparisons limit certainty.
Limitation: Indirect cross-trial comparison using digitized Kaplan-Meier data, not a head-to-head randomized trial.
Source: Urol Oncol · PubMed 43009427 · DOI 10.1016/j.urolonc.2026.10.005
Loading today's edition…